Literature DB >> 750103

Correlations between experimental chemotherapy in the murine glioma and effectiveness of clinical therapy regimens.

V A Levin, C B Wilson.   

Abstract

Intracerebral murine glioma 26 was used as a model system for evaluating two-drug combinations of antitumor agents, BCNU was combined with either procarbazine, dianhydrogalactitol, or ellipticine. CCNU was combined with procarbazine. All combinations were more active than the individual drugs alone. The most potent combinations achieved 85-100% tumor "cure" at 120 days, with combined toxicity indices of 0.25 (CCNU-procarbazine) to 1.30 (NCNU-dianhydrogalactitol). The experimental data were compared to clinical studies with CCNU, procarbazine, and vincristine, and BCNU-procarbazine.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 750103     DOI： 10.1007/bf00253145

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  17 in total

1.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.

Authors:  E A GEHAN
Journal:  Biometrika       Date:  1965-06       Impact factor: 2.445

2.  A mouse ependymoblastoma as an experimental model for screening potential antineoplastic drugs.

Authors:  R I Geran; G F Congleton; L E Dudeck; B J Abbott; J L Gargus
Journal:  Cancer Chemother Rep 2       Date:  1974-12

3.  Studies on the chemotherapy of experimental brain tumors: evaluation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, vincristine, and 5-fluorouracil.

Authors:  W R Shapiro
Journal:  J Natl Cancer Inst       Date:  1971-02       Impact factor: 13.506

4.  Studies on the chemotherapy of experimental brain tumors: evaluation of 1,3-bis(2-chloroethyl)-l-nitrosourea, cyclophosphamide, mithramycin, and methotrexate.

Authors:  W R Shapiro; J I Ausman; D P Rall
Journal:  Cancer Res       Date:  1970-09       Impact factor: 12.701

5.  Methoxy-9-ellipticine lactate. 3. Clinical screening: its action in acute myeloblastic leukaemia.

Authors:  G Mathé; M Hayat; F De Vassal; L Schwarzenberg; M Schneider; J R Schlumberger; C Jasmin; C Rosenfeld
Journal:  Rev Eur Etud Clin Biol       Date:  1970-05

6.  The application of brain capillary permeability coefficient measurements to pathological conditions and the selection of agents which cross the blood-brain barrier.

Authors:  V A Levin; H D Landahl; M A Freeman-Dove
Journal:  J Pharmacokinet Biopharm       Date:  1976-12

Review 7.  Chemotherapy: the agents in current use.

Authors:  V A Levin; C B Wilson
Journal:  Semin Oncol       Date:  1975-03       Impact factor: 4.929

8.  BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors.

Authors:  V A Levin; D C Crafts; C B Wilson; M J Schultz; E B Boldrey; K J Enot; T L Pischer; M Seager; R M Elashoff
Journal:  Cancer Treat Rep       Date:  1976-03

9.  Permeability characteristics of brain adjacent to tumors in rats.

Authors:  V A Levin; M Freeman-Dove; H D Landahl
Journal:  Arch Neurol       Date:  1975-12

10.  Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors.

Authors:  P H Gutin; C B Wilson; A R Kumar; E B Boldrey; V Levin; M Powell; K J Enot
Journal:  Cancer       Date:  1975-05       Impact factor: 6.860
View more
  5 in total

1.  Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen.

Authors:  M D Prados; M S Edwards; J Rabbitt; K Lamborn; R L Davis; V A Levin
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

2.  Blood-brain barrier integrity and host responses in experimental metastatic brain tumours.

Authors:  N H Greig; H B Jones; J B Cavanagh
Journal:  Clin Exp Metastasis       Date:  1983 Jul-Sep       Impact factor: 5.150

3.  Radiotherapy and combination chemotherapy with carmustine, vincristine, and procarbazine (BVP) in primary brain tumors.

Authors:  G Comella; G Scoppa; M De Marco; G P Ianniello; G Melillo; F Coucourde; D Zarrilli
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

4.  Malignant gliomas treated after surgery by combination chemotherapy and delayed irradiation. Part I: Analysis of results.

Authors:  M Poisson; P Pouillart; J P Bataini; R Mashaly; B F Pertuiset; J Metzger
Journal:  Acta Neurochir (Wien)       Date:  1979       Impact factor: 2.216

5.  Chemotherapeutic approaches to brain tumors. Experimental observations with dianhydrogalactitol and dibromodulcitol.

Authors:  V A Levin; K T Wheeler
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.